Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463253 · ClinicalTrials.gov registry record
Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients
A clinical trial, sponsored by University of California, Davis.
- Completed
- Registry status
- 20
- Enrollment target
NCT02463253: Completed study, sponsored by University of California, Davis.
NCT02463253 is a clinical trial that has completed, run by University of California, Davis. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02463253 has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (AR) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) in blood, urine and kidney tissue (biopsy) in kidney transplant recipients. Proteogenomic profiles will be routinely monitored over one year after enrollment.
Primary Outcome
Incidence of acute rejection at the time of any kidney biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-05 |
What the finished NCT02463253 record still lists
NCT02463253 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02463253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02463253 about?
NCT02463253 is a clinical study titled "Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients". This is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (AR) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) in blood, urine and kidney tissue (biopsy) in kidney transplan...
What is the current status of trial NCT02463253?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2015-04. Estimated completion is 2016-05.
Who is sponsoring clinical trial NCT02463253?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia